Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) was once the ultimate pariah stock—one investors wouldn’t touch with a 10-foot pole. The Israeli drugmaker was crushed under staggering opioid-related legal liabilities, a mountain of debt, and an overreliance on low-margin generics that left it teetering on the brink.
Today, that narrative has been completely rewritten. Teva’s shares have more than doubled over the past 12 months, and Wall Street has turned overwhelmingly bullish. What was once written off as a broken company has pulled off one of the most impressive corporate turnarounds in recent pharmaceutical history.
Just three years ago, Teva’s future looked bleak. As the world’s largest generic drug manufacturer, it faced brutal industry-wide pricing pressure that eroded margins. But its biggest problems were self-inflicted: billions in opioid-related legal claims and a debt load that threatened its solvency.
The company has since addressed both head-on. Teva has slashed its outstanding debt by more than $5 billion and fully resolved all major opioid-related legal disputes. As of March 31, 2026, its financial leverage ratio stood at 67%, a dramatic improvement from the crisis-era levels that spooked investors. It’s also on track to deliver $470 million in net cost savings this year through its restructuring program.
The most profound change, however, is in Teva’s business model. Generics, once the company’s entire identity, now account for just over 50% of total sales. Branded pharmaceuticals will soon become the majority of Teva’s annual revenue, marking the end of its era as a pure-play generic drug maker.
Teva’s transformation is already delivering results. While first-quarter total sales dipped 1% year-over-year to $4 billion, that decline was entirely driven by a 13% drop in generic revenue. Its branded drug portfolio, by contrast, is firing on all cylinders.
Huntington’s disease treatment Austedo led the charge with $578 million in sales, up 41% from a year ago. Migraine prevention drug Ajovy grew 35% to $196 million, and schizophrenia treatment Uzedy posted a stunning 62% jump to $63 million. Even its legacy generic business is evolving, with a shift toward higher-margin biosimilars expected to generate $800 million in annual revenue by 2027.
But what has Wall Street truly excited is Teva’s pipeline. Between 2026 and 2030, the company is poised to launch blockbuster therapies for schizophrenia, asthma, and ulcerative colitis that could add up to $7 billion in annual sales. It’s also bolstering its pipeline through acquisitions, most notably its $700 million deal for Emalex Biosciences and its lead Tourette syndrome candidate ecopipam. Analysts at Jefferies estimate ecopipam could reach $1 billion in peak annual sales.
Even after doubling in value, Teva still looks like a bargain. The stock trades at just 13 times forward earnings, well below the healthcare sector average of 16.5 times.
Wall Street’s confidence is reflected in analyst ratings. Of the 13 analysts surveyed by S&P Global in May, 12 rated Teva a “buy” or “strong buy,” with only one hold recommendation. The consensus 12-month price target implies an additional 11% upside from current levels.
Evercore ISI analyst Umer Raffat called the potential FDA approval later this year of Teva’s long-acting schizophrenia drug TEV-749 the company’s “most meaningful catalyst” for further gains.
To be sure, risks remain. Lingering litigation uncertainty, persistent generic pricing pressure, and the ever-present threat of clinical trial setbacks could still derail progress. But Teva is no longer a company in crisis. It has emerged from its darkest days as a leaner, more focused growth play—proof that even the most written-off stocks can stage remarkable comebacks.
